Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Biogen Inc
Recent news which mentions Biogen Inc
< Previous
1
2
3
Next >
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Today 8:42 EDT
Tags
Eisai Co Ltd
Health care industry
Eli Lilly and Co
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
Eli Lilly and Co
Eisai Co Ltd
Mad Money
From
CNBC.com News
Cramer's Lightning Round: Bank of America is a buy
May 10, 2024
Tags
Bank of America Corp
S&P 500
Mad Money
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Eisai Co Ltd
Health care industry
Earnings
From
CNBC.com News
5 things to know before the stock market opens Monday
April 22, 2024
Tags
Politics
Investment strategy
Alphabet Inc
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Biotech and Pharmaceuticals
Eisai Co Ltd
Eli Lilly and Co
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Biotech and Pharmaceuticals
Health & Science
Biogen Inc
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Biogen Inc
Biotechnology
Companies
From
CNBC.com News
5 things to know before the stock market opens Monday
February 12, 2024
Tags
Economy
Tesla Inc
PepsiCo Inc/
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Business News
Health & Science
Biogen Inc
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Biotechnology
Biogen Inc
US: News
From
CNBC.com News
5 things to know before the stock market opens Monday
November 06, 2023
Tags
Investing
Biogen Inc
Economy
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Biotech and Pharmaceuticals
Eisai Co Ltd
Health care industry
From
CNBC.com News
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
August 07, 2023
Tags
SAGE Therapeutics Inc
Drug approvals
Breaking news
From
CNBC.com News
Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more
July 28, 2023
Tags
Markets
Pfizer Inc
Market Insider
From
CNBC.com News
Stocks making the biggest moves midday: Spotify, RTX, General Electric and more
July 25, 2023
Tags
Business
Breaking News: Markets
Stock markets
From
CNBC.com News
Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
July 25, 2023
Tags
Business
Pharmaceuticals
Wells Fargo & Co
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Markets
Politics
Investment strategy
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Alzheimer's disease
Breaking news
Business
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Business News
Breaking News: Business
Health & Science
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Business News
Health & Science
Biogen Inc
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
Meta Platforms Inc
Economy
Biogen Inc
From
CNBC.com News
Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more
July 07, 2023
Tags
First Solar Inc
Alibaba Group Holding Ltd
Market Insider
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Biotech and Pharmaceuticals
Biogen Inc
Social issues
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Biotech and Pharmaceuticals
Politics
Health care industry
From
CNBC.com News
Stocks making the biggest moves midday: JD.Com, Biogen, Oracle and more
June 13, 2023
Tags
Business
Transocean Ltd
Stock markets
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
Eisai Co Ltd
Health care industry
U/S/ Economy
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
Alzheimer's disease
Business
US Economy
From
CNBC.com News
Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on
May 15, 2023
Tags
Stock markets
stocks
Food and drink
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Business
Alzheimer's disease
Business News
From
CNBC.com News
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.